In Vitro and In Vivo activities of the novel ketolide RBx 14255 against Clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5986-5989

  Kumar, Manoj ^a,c   Mathur, Tarun ^a,c   Barman, Tarani K ^a,c   Ramkumar, G ^a,c   Bhati, Ashish ^a   Shukla, Gunjan ^a   Kalia, Vandana ^a,c   Pandya, Manisha ^a,c   Raj, V Samuel ^a,c   Upadhyay, Dilip J ^a,c   Vaishnavi, Chetana ^b   Chakrabarti, Anjan ^a   Das, Biswajit ^a,c   Bhatnagar, Pradip K ^a,c  

^a RANBAXY RESEARCH LABORATORIES   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CLINDAMYCIN PHOSPHATE; ERYTHROMYCIN; KETOLIDE; METRONIDAZOLE; PLACEBO; RBX 14255; TELITHROMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DRUG EFFICACY; FUSOBACTERIUM NUCLEATUM; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CRICETINAE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; KETOLIDES; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; SURVIVAL RATE; VANCOMYCIN;

EID: 84868009588     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00015-12     Document Type: Article

References (18)

1. Anton PM, et al. 2004. Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob. Agents Chemother. 48:3975-3979.
2. Barbut F, et al. 2000. Epidemiology of recurrences or reinfection of Clostridium difficile-associated diarrhea. J. Clin. Microbiol. 38:2386-2388.
3. Centers for Disease Control and Prevention. 2005. Clostridium difficile information for healthcare providers. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/ncidod/dhqp/id-CdiffFAQ-HCP.html. Accessed 26 November 2007.
4. Credito KL, Ednie LM, Appelbaum PC. 2008. Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis. Antimicrob. Agents Chemother. 52:365-373.
5. Deneve C, Janoira C, Poilaneb I, Fantinatob C, Collignona A. 2009. New trends in Clostridium difficile virulence and pathogenesis. Int. J. Antimicrob. Agents 33:S24-S28.
6. Gerding DN, Jr, et al. 1986. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch. Intern. Med. 146:95-100.
7. Hookman P, Barkin JS. 2009. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 15:1554-1580.
8. Kalia V, et al. 2009. Mode of action of ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes. Antimicrob. Agents Chemother. 53:1427-1433.
9. Lyras D, et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-1179.
10. Mathur T, et al. 2011. Activity of RBx 11760, a novel biaryl oxazolidinone, against Clostridium difficile. J. Antimicrob. Chemother. 66:1087-1095.
11. McCusker ME, Harris AD, Perencevich EE, Roghmann MC. 2003. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. Dis. 9:730-733.
12. Modena S, Bearelly D, Swartz K, Friedenberg FK. 2005. Clostridium difficile among hospitalized patients receiving antibiotics: a case-control study. Infect. Control Hosp. Epidemiol. 26:685-690.
13. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 6th ed: approved standard M11-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
14. Ochsner UA, et al. 2009. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J. Antimicrob. Chemother. 63:964-971.
15. Pandya M, et al. 2010. Activity of a novel series of acylides active against community acquired respiratory pathogens. Int. J. Antimicrob. Agents. 36:169-174.
16. Siegel DL, Edelstein PH, Nachamkin I. 1990. Inappropriate testing for diarrheal diseases in the hospital. JAMA 263:979-982.
17. Tanikawa T, et al. 2003. Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl) acetylerythromycin A derivatives. J. Med. Chem. 46:2706-2715.
18. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45:302-307.